SCHEMBL700868

SCHEMBL700868

CN1CCCN(C(=O)c2ccc(F)c(-c3ccc(C=C4C(=O)Nc5ccc(Cl)cc54)o3)c2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 12/20 1.00
PIM2 Q9P1W9 12/20 1.00
FLT3 P36888 2/20 0.78
PIM3 Q86V86 1/20 0.78
KMT2A Q03164 3/20 0.44
LRRK2 Q5S007 2/20 0.42
PTPN2 P17706 1/20 0.41
PTPN1 P18031 1/20 0.41
MEN1 O00255 2/20 0.40
RPS6KA3 P51812 1/20 0.40
CDK5 Q00535 1/20 0.40
CDK5R1 Q15078 1/20 0.40
PSEN1 P49768 1/20 0.40
PSEN2 P49810 1/20 0.40
APH1B Q8WW43 1/20 0.40
NCSTN Q92542 1/20 0.40
APH1A Q96BI3 1/20 0.40
PSENEN Q9NZ42 1/20 0.40
MET P08581 1/20 0.40
CCNE1 P24864 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL700867 1.00 PIM1 (1.00) PIM1PIM2FLT3PIM3KMT2A
SCHEMBL10091752 1.00 PIM1 (1.00) PIM1PIM2FLT3PIM3KMT2A
SCHEMBL702181 0.95 PIM1 (0.90) PIM1PIM2FLT3PIM3KMT2A
SCHEMBL702180 0.95 PIM1 (0.90) PIM1PIM2FLT3PIM3KMT2A
SCHEMBL10091753 0.95 PIM1 (0.90) PIM1PIM2FLT3PIM3KMT2A
SCHEMBL10091720 0.90 PIM1 (0.84) PIM1PIM2FLT3PIM3KMT2A
SCHEMBL10091730 0.88 PIM1 (0.85) PIM1PIM2FLT3PIM3KMT2A
SCHEMBL10091584 0.88 PIM1 (1.00) PIM1PIM2FLT3PIM3KMT2A
SCHEMBL706812 0.88 PIM1 (1.00) PIM1PIM2FLT3PIM3KMT2A
SCHEMBL706813 0.88 PIM1 (1.00) PIM1PIM2FLT3PIM3KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120190669-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. (US) 2012-07-26 US disclosed
US-8124649-B2 Oxindole compounds CYLENE PHARMACEUTICALS, INC. (US) 2012-02-28 US disclosed
EP-2307421-A1 OXINDOLE COMPOUNDS Cylene Pharmaceuticals, Inc. (US) 2011-04-13 EP disclosed
US-20100041635-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. 2010-02-18 US disclosed
WO-2010002933-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041635-A1 OXINDOLE COMPOUNDS FLT3, PIM1, PIM2 PIM1 2/4885PIM2 3/4885FLT3 1/4885
US-20120190669-A1 OXINDOLE COMPOUNDS FLT3, PIM1, PIM2 PIM1 2/4885PIM2 3/4885FLT3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.